Navigation Links
Syndax Pharmaceuticals to Present at Biotech Showcase 2011
Date:1/4/2011

WALTHAM, Mass., Jan. 4, 2011 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced that Joanna Horobin, M.D., the company's president and CEO, will present at the Biotech Showcase 2011 on Tuesday, January 11, 2011 at 10:00 a.m. PT at the Parc 55 Wyndham hotel in San Francisco. Dr. Horobin's presentation will include the recently reported results from a randomized phase 2 study, which showed a four-month survival advantage when entinostat was added to erlotinib in patients with lung cancers expressing high levels of E-cadherin. In addition, she will review the ongoing phase 2 clinical programs for entinostat in breast, lung, colorectal cancer and hematologic malignancies.

The presentation will be available at Syndax's website, www.syndax.com.

About Syndax Syndax Pharmaceuticals, Inc. is a Waltham, MA-based, oncology-focused pharmaceutical company. Syndax is building a portfolio of new oncology products to extend and improve the lives of patients by developing and commercializing novel cancer therapies in optimized, mechanistically driven combination regimens. Formed in 2005, the company's intellectual property is based on work from scientific founder Ronald Evans, Ph.D., recipient of the 2004 Albert Lasker Prize for Basic Medical Research, a Member of the National Academy of Sciences, a professor at the Salk Institute for Biological Studies and a Howard Hughes Medical Institute Investigator. Syndax has worldwide rights to develop and commercialize entinostat and is backed by top-tier Venture Capital firms: Domain Associates, MPM Capital, Avalon, Pappas and Forward Ventures. For more information please visit www.syndax.com. Contact Information E. Blair Schoeb Syndax Pharmaceuticals, Inc. Tel: 908-277-0386 bschoeb@syndax.com
'/>"/>

SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Syndax Pharmaceuticals Entinostat in Combination Shows Activity in Breast Cancer
2. Syndax Pharmaceuticals Entinostat Plus Erlotinib Improves Survival in Select NSCLC Patients
3. Syndax Pharmaceuticals Announces Issuance of UK Patent for Entinostat
4. Syndax Pharmaceuticals to Present at Sachs Biotech in Europe Investor Forum
5. Syndax Pharmaceuticals Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer
6. Amylin Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
7. VIDEO from Endo Pharmaceuticals Available on thenewsmarket.com: FDA Approves New Treatment for Low Testosterone
8. Lotus Pharmaceuticals Announces Approval of Reverse Stock Split
9. Cumberland Pharmaceuticals Announces Voluntary Recall of Acetadote® Vials
10. Endo Pharmaceuticals Receives FDA Approval for FORTESTA™ (Testosterone) Gel as a Class III Product for Topical Use for Men with Low Testosterone
11. Reportlinker Adds E7: The Outlook for Pharmaceuticals to 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... York , May 23, 2016 ... report titled, " Exocrine Pancreatic Insufficiency Market - Global ... - 2023 ." According to the report, the exocrine ... CAGR of 8.3% from 2015 to 2023 to reach ... (EPI) is a condition characterized by the deficiency of ...
(Date:5/23/2016)... -- Non-invasive diagnostic test realizes the potential ... to be presented at Yissum’s booth, at IATI-BIOMED 2016 ... of the Hebrew University of Jerusalem announced today ... Ventures MKI, the technology investment arm of Morris Kahn ... for early detection of multiple diseases by analyzing circulating ...
(Date:5/23/2016)... 2016   Purdue Pharma L.P.  today announced ... with Egalet Corporation and Acura Pharmaceuticals, Inc. that ... the agreement the companies will exchange valuable patent ... companies to develop and sell several opioid pain ... reflects the commitment of Purdue Pharma to seek ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... May 24, 2016 , ... Mental health watchdog Citizens Commission on ... and renowned professor of psychiatry Thomas Szasz, is continuing its protest against the use ... Death” exhibit in Atlanta, Georgia. The opening of the exhibit follows CCHR’s recent protest ...
(Date:5/24/2016)... , ... May 24, 2016 , ... Loma Linda University ... new adult hospital and expanded Children’s Hospital. Over 3,000 people looked on as the ... Check out the event photo slidehsow. , During the program, Richard H. Hart, ...
(Date:5/24/2016)... ... , ... Backed by decades of experience, Metroloji Okulu works ... best suited solution to meet regulatory requirements. Their professional staff also performs on-site ... , Metroloji Okulu specializes in MadgeTech’s line of medical and pharmaceutical data ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... Growing in ... growing trend, more gluten-free products are available and easily accessible. Whether someone chooses to ... to cater to a certain diet, King Kullen Grocery stocks their shelves with many ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... by 9.3 million people, or 10% over last year, according to data in ... under group policies was comparatively stable, with a slight decrease in risk-based groups ...
Breaking Medicine News(10 mins):